PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
21.62%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.45%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
39.20%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.38%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-255.04%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 10.71%. Seth Klarman would check if external or internal factors caused the decline.
-255.04%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 10.61%. Seth Klarman would check if structural or cyclical issues are at play.
102.01%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.54%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
60.99%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.26%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
101.35%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 19.23%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
16.05%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
14.82%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-96.29%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-212.61%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6217.76%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.31%. Joel Greenblatt might see a short-term competitive advantage at play.
103.53%
OCF/share CAGR of 103.53% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
112.04%
OCF/share CAGR of 112.04% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
102.33%
3Y OCF/share growth of 102.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
387.66%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 22.47% over a decade. Joel Greenblatt might see a standout compounder of earnings.
2084.63%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 42.55%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
232.29%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 7.77%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
2867.95%
Equity/share CAGR of 2867.95% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
4806.10%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 3.72%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
1601.21%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 6.07%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
830.66%
AR growth of 830.66% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
36.09%
Inventory growth of 36.09% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
95.84%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.25%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
66.82%
BV/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
19.54%
Debt growth of 19.54% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
38.52%
R&D growth of 38.52% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
69.20%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.